Home » MAYNE CONTINUES DEVELOPMENT OF PLIVA G-CSF
MAYNE CONTINUES DEVELOPMENT OF PLIVA G-CSF
PLIVA, headquartered at Croatia, has finalized an agreement with Mayne Pharma of Australia, for the continued development of biosimilar granulocyte-colony stimulating factor (G-CSF) for the European, South East Asian, Middle Eastern and Asia Pacific markets.
BioSpectrum (http://www.biospectrumasia.com/content/280706AUS1235.asp)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May